Stanford University
Showing 6,821-6,840 of 13,044 Results
-
Bingwei Lu
Professor of Pathology
Current Research and Scholarly InterestsWe are interested in understanding how neural stem cells balance their self-renewal and differentiation and how deregulation of this process can result in brain tumor. We are also interested in mechanisms of neurodegeneration in Alzheimers and Parkinsons diseases. We are using both Drosophila and mammalian models to address these fundamental questions.
-
Lu,Guolan
Assistant Professor of Urology
Current Research and Scholarly InterestsThe Lu Lab develops and integrates AI, spatial multi-omics, and advanced imaging to understand and model how cells, tissues, and therapeutic agents interact in their native spatial context, and how these interactions drive disease progression and treatment response.
-
Janice Lu
Clinical Professor, Medicine - Oncology
BioDr. Janice Lu is Clinical Professor of Medicine in the Division of Medical Oncology at Stanford University School of Medicine. She specializes in the treatment of breast cancer, with expertise in hormone receptor–positive and HER2-positive disease, antibody-drug conjugates, and immunotherapy. Dr. Lu has led and contributed to multiple clinical trials, including playing a key role in the EMERALD trial, which resulted in FDA approval of the first oral SERD for ESR1-mutated ER+/HER2- metastatic breast cancer. Her translational research focuses on liquid biopsy, epigenetics, AI and multiomics approaches to treatment resistance. She has chaired national sessions on precision oncology and holds leadership roles with NRG Oncology and ASCO, including Vice-Chair of the NRG Immunotherapy Subcommittee and Track Leader for ASCO’s Developmental Therapeutics and Targeted Therapy Education Program. She has also served on committees for the National Comprehensive Cancer Network (NCCN) and the Southwest Oncology Group (SWOG).
Dr. Lu completed her Hematology and Oncology fellowship at New York University School of Medicine and earned a PhD in epigenetics under the mentorship of late Dr. David Allis, a pioneer in the field and 2018 Lasker Laureate. Prior to joining Stanford, she was Director of Breast Medical Oncology and led the Circulating Tumor Cell (CTC) Core Lab at Northwestern University Feinberg School of Medicine, before returning to the Bay Area to be with her family and to further expand research and patient-centered care. -
Junjie Lu
Ph.D. Student in Epidemiology and Clinical Research, admitted Autumn 2023
BioJunjie's research is centered on the social determinants of minority health, epidemiological methods, and clinical effectiveness. He is deeply committed to understanding the health disparities faced by minority populations. His clinical background helps bridge the gap between research and practical application, aiming to improve healthcare outcomes in real-world settings.
Junjie Lu earned a Master of Public Health degree from the Harvard T.H. Chan School of Public Health, where he concentrated on Health and Social Behavior. He also holds an MBBS and an MS from Shanghai University of Traditional Chinese Medicine. Junjie gained practical experience as an intern doctor at a university hospital for two years, during which he led a pilot randomized controlled trial on the effects of acupuncture on depressive symptoms. -
Sydney X. Lu
Assistant Professor of Medicine (Hematology)
BioSydney Lu is an assistant professor and physician-scientist in the Division of Hematology, Department of Medicine with a broad interest in both normal and abnormal RNA processing in the context of normal physiology and disease states. The laboratory studies translational questions regarding the mechanistic basis of RNA processing abnormalities in malignant blood disorders, their implications for leukemogenesis and cancer biology, as well as resultant therapeutic opportunities.
As a physician, Sydney’s group is particularly focused on dissecting RNA processing abnormalities in primary patient samples and disease-relevant preclinical model systems. Lab members employ a variety of ‘wet-lab’ and computational approaches to study transcriptome abnormalities in (1) states of immune dysfunction, (2) myeloid blood cancers such as myelodysplastic syndromes and acute myeloid leukemia, and (3) lymphoid blood cancers such as chronic lymphocytic leukemia. Additional projects are focused on novel therapeutics, including multiple targeted agents which modulate RNA processing, for the selective treatment of these diseases.
Sydney’s research is/has been supposed by grant funding from the National Cancer Institute, Parker Institute for Cancer Immunotherapy, Leukemia & Lymphoma Society, Aplastic Anemia & Myelodysplastic Syndromes International Foundation, the American Society for Clinical Oncology, the American Society of Hematology, the American Association for Cancer Research, the Paula and Rodger Riney Foundation, the Doris Duke Charitable Foundation, The Gabrielles Angel Foundation for Cancer Research, and the Stanford Cancer Institute. -
Wan-Jin Lu
Basic Life Research Scientist, Stem Cell Bio Regenerative Med Institute
BioDr. Wan-Jin Lu is a Research Scientist in Dr. Phil Beachy's lab. Wan-Jin grew up in Taiwan, obtained her B.S. in Zoology at National Taiwan University and completed her PhD in Genetics and Development at UT Southwestern in the lab of Dr. John Abrams. Her Ph.D. research involved the identification of the evolutionary conserved function of the tumor suppressor gene p53 that ensures the quality control of germ cells. She then moved to the Bay Area, where she was a Damon Runyon Postdoctoral Fellow in the Institute of Stem Cell Biology and Regenerative Medicine in the Beachy lab. Her work currently focuses on understanding the function of Hedgehog signaling in taste receptor cell homeostasis and delineating the mechanisms of taste receptor regeneration after chemotherapy-induced loss.
Since 2017, she has been collaborating with Tabula Muris And Tabula Sapiens Consortium to investigate taste receptor stem cell renewal and regeneration in the Beachy lab. Her work has received funding support from California Institute of Regenerative Medicine (CIRM), Thomas and Stacey Siebel Foundation, and NIH (R21 and R01).
